Compare

Liraglutide vs MK-677

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Liraglutide

2186 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 50% · Mixed 40% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
-143
Lean mass
-120
Joint comfort
-72
Recovery
-111
Digestive comfort
-26

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-47
Appetite loss
-41
Injection site reaction
-108
Anxiety
-116
Flushing
-27

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–3 mg

0.05–0.1 mg
9
0.1–0.2 mg
17
0.2–0.4 mg
20
0.4–0.6 mg
25
0.6–1 mg
17
1–2 mg
14
2–3 mg
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing30stacking43side effects16liraglutide19

How repeat users are trending

Among repeat reporters, 60% said they felt similar to their last entry, 30% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 481 repeat reporters

MK-677

503 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
-122
Digestive comfort
-163
Skin appearance
-123
Appetite control
-140
Energy
-97

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-26
Flushing
-83
Headache
-158
GI discomfort
-145
Dizziness
-98

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.2–5 mg

0.2–0.4 mg
10
0.4–0.6 mg
12
0.6–1 mg
17
1–2 mg
9
2–3 mg
10
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking20side effects13mk-67711

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 111 repeat reporters

Sources (12)

Published sources linked on the Liraglutide and MK-677 wiki pages.

  1. FDA Drug Label

    SAXENDA (liraglutide) injection — Prescribing Information

    Novo Nordisk. FDA Drug Label. 2014

    Source
    Wiki study page →
  2. FDA Drug Label

    VICTOZA (liraglutide) injection — Prescribing Information

    Novo Nordisk. FDA Drug Label. 2010

    Source
    Wiki study page →
  3. PubMed

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)

    Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016

    Source
    Wiki study page →
  4. PubMed

    A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)

    Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015

    Source
    Wiki study page →
  5. PubMed

    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

    Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022

    Source
    Wiki study page →
  6. PubMed

    Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

    Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020

    Source
    Wiki study page →
  7. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  8. PubMed

    MK-677, an orally active growth hormone secretagogue: effects on body composition

    Murphy MG, Plunkett LM, Gertz BJ, et al. J Clin Endocrinol Metab. 1998

    Source
    Wiki study page →
  9. PubMed

    Two-year treatment with ibutamoren increases bone mineral density, body composition, and quality of life

    Nass R, Pezzoli SS, Oliveri MC, et al. J Clin Endocrinol Metab. 2008

    Source
    Wiki study page →
  10. ClinicalTrials.gov

    Ibutamoren (MK-677) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  11. PubMed

    MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism

    Murphy MG, Plunkett LM, Gertz BJ, et al. The Journal of clinical endocrinology and metabolism. 1998

    Source
    Wiki study page →
  12. PubMed

    Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control

    Philip M, Karakka Kal AK, Subhahar MB, et al. Rapid communications in mass spectrometry : RCM. 2022

    Source
    Wiki study page →